COMMUNIQUÉS West-GlobeNewswire

Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026
30/07/2026
SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for [...]
Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026
30/07/2026
FLORHAM PARK, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of [...]
NurExone Launches Bioprocess Optimization Initiative to Support Commercial and Clinical Readiness
30/07/2026
TORONTO and HAIFA, Israel, July 30, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX, OTCQB: NRXBF, FSE: J90) (“ NurExone ” or the “ Company ”), a biotechnology company developing exosome-based regenerative [...]
Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference
30/07/2026
MIAMI, FL, July 30, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory [...]
SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET
30/07/2026
MIAMI, July 30, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and [...]
Clearmind Announces Positive Safety Findings for CMND 100, Demonstrating Consistent Tolerability Throughout Full Dose Escalation in Part A of its FDA-Regulated Clinical Trial
30/07/2026
Vancouver, Canada, July 30, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage biotechnology company pioneering nonhallucinogenic neuroplastogenderived treatments for Alcohol Use Disorder [...]
NewGen Provides Update on K25.ai Investment and Strengthened Financial Position
30/07/2026
NewGen’s total shares outstanding count expected to reach 5.9 million following recently announced share issuance, bolstering market capitalization NewGen’s agreed 13% stake in K25.ai is now valued at approximately US$ [...]
Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer
30/07/2026
REVTORPYK (gedatolisib) in combination with fulvestrant, with or without palbociclib, listed as a preferred Category 1 regimen for second-line or subsequent treatment for tumors without a PIK3CA mutation following [...]
Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update
30/07/2026
Completed Type A meeting with the FDA on bitopertin and aligned that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response; topline data expected in Q4 2026 Launched Expanded Access Program ( [...]
Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology
30/07/2026
Publication helps establish the efficacy and safety profile of of CTx-1301, reinforcing the potential of Cingulate’s Precision Timed Release™ platform technology KANSAS CITY, Kan., July 30, 2026 (GLOBE NEWSWIRE) -- [...]
Lite Strategy Repurchases 13% of Outstanding Shares Since December, Increasing Litecoin Backing Per Share
30/07/2026
Lite Strategy Buys Back Roughly 4.9 Million Shares at an Average Price of $1.11 with No Debt Incurred SAN DIEGO, July 30, 2026 (GLOBE NEWSWIRE) -- Lite Strategy, Inc. (Nasdaq: LITS) (“Lite Strategy” or the “Company”), [...]
Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026
30/07/2026
THE WOODLANDS, Texas, July 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its second quarter 2026 financial results on Thursday, August 6, 2026, prior [...]
20/20 BioLabs to Host Investor Webinar on August 5, 2026, to Discuss Commercial Opportunities Following Management’s Recent East Asia Business Development Tour
30/07/2026
Chief Executive Officer Jonathan Cohen to Discuss BIO Asia-Taiwan Participation and Strategic Meetings in Taipei, Tokyo, and Seoul Webinar to Be Held Wednesday, August 5, 2026 at 12:00 p.m. Eastern Time; Registration Is [...]
Glow Peptide Stack Launched by Kylo Peptides for Laboratory Use
30/07/2026
Sheridan, Wyoming , July 30, 2026 (GLOBE NEWSWIRE) -- Kylo Peptides has announced that it has added the GLOW peptide stack to its research catalog. The product supplies three separately sealed, lyophilized vials of the [...]
Relation Announces Expanded Collaboration with GSK
30/07/2026
Up to $110 million upfront and success-based milestones collaboration will generate large-scale human cellular perturbation datasets to advance understanding of disease biology LONDON, July 30, 2026 (GLOBE NEWSWIRE) -- [...]
Actimed Therapeutics Strengthens Board with Appointment of Dr. Anders Ullman
30/07/2026
London, UK – 30 July 2026. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting [...]
Relation unveils MORGAN, the next-generation model of cellular biology
30/07/2026
LONDON, July 30, 2026 (GLOBE NEWSWIRE) -- Relation today announced MORGAN (Multi-Omic Regulatory Genomics using Artificial Neural Networks), our flagship cellular foundation model designed to transform how new biology [...]
HorseFil Confirms Its Official Website and 2026 Package Pricing Amid Similarly Named Sites
30/07/2026
HorseFil's Tongkat Ali, Maca, and Ashwagandha Amounts, 60-Day Guarantee Terms, and Medication Interaction Details Explained Ogden, UT, July 29, 2026 (GLOBE NEWSWIRE) -- These statements have not been evaluated by the [...]
Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic use
30/07/2026
For investor audiences and media only Second quarter 2026 total revenues decreased by 3% to US$90.2 million, compared to the second quarter 2025 RUCONEST® revenue was US$72.3 million, a 10% decrease compared to the [...]

Pages